PTC Therapeutics, Inc.
NASDAQ:PTCT
42.96 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 937.822 | 698.801 | 538.593 | 380.766 | 306.98 | 264.734 | 194.392 | 82.705 | 36.766 | 22.963 | 31.326 | 28.779 | 98.961 |
| Cost of Revenue
| 288.121 | 44.678 | 32.328 | 18.942 | 12.135 | 12.67 | 4.577 | 117.633 | 121.816 | 79.838 | 54.875 | -5.167 | 0 |
| Gross Profit
| 649.701 | 654.123 | 506.265 | 361.824 | 294.845 | 252.064 | 189.815 | -34.928 | -85.05 | -56.875 | -23.549 | 33.946 | 98.961 |
| Gross Profit Ratio
| 0.693 | 0.936 | 0.94 | 0.95 | 0.96 | 0.952 | 0.976 | -0.422 | -2.313 | -2.477 | -0.752 | 1.18 | 1 |
| Reseach & Development Expenses
| 666.563 | 651.496 | 540.684 | 477.643 | 257.452 | 171.984 | 117.456 | 117.633 | 121.816 | 79.838 | 54.875 | 46.139 | 58.677 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 153.548 | 121.271 | 97.13 | 82.08 | 44.82 | 25.219 | 14.615 | 16.153 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 332.54 | 325.998 | 285.773 | 245.164 | 202.541 | 153.548 | 121.271 | 97.13 | 82.08 | 44.82 | 25.219 | 14.615 | 16.153 |
| Other Expenses
| 10.13 | 116.554 | 54.751 | 36.892 | 27.65 | 0.129 | -1.279 | -1.207 | -0.465 | -0.213 | 0.038 | 1.783 | 0.461 |
| Operating Expenses
| 999.103 | 1,094.048 | 881.208 | 759.699 | 487.643 | 348.409 | 254.107 | 214.763 | 203.896 | 122.376 | 76.724 | 55.587 | 68.379 |
| Operating Income
| -349.402 | -439.925 | -374.943 | -397.875 | -192.798 | -115.685 | -64.292 | -132.058 | -167.13 | -99.413 | -45.397 | -26.808 | 30.582 |
| Operating Income Ratio
| -0.373 | -0.63 | -0.696 | -1.045 | -0.628 | -0.437 | -0.331 | -1.597 | -4.546 | -4.329 | -1.449 | -0.932 | 0.309 |
| Total Other Income Expenses Net
| -346.708 | -147.562 | -143.397 | -5.057 | -47.128 | -19.211 | -1.279 | -1.207 | -0.465 | -0.213 | -0.092 | 1.783 | 0.461 |
| Income Before Tax
| -696.11 | -587.487 | -518.34 | -402.932 | -239.926 | -128.11 | -77.665 | -141.541 | -169.962 | -98.446 | -51.574 | -26.235 | 28.599 |
| Income Before Tax Ratio
| -0.742 | -0.841 | -0.962 | -1.058 | -0.782 | -0.484 | -0.4 | -1.711 | -4.623 | -4.287 | -1.646 | -0.912 | 0.289 |
| Income Tax Expense
| -69.506 | -28.47 | 5.561 | 35.228 | 11.65 | -0.029 | 1.335 | 0.569 | 0.485 | -4.693 | 6.214 | 1.21 | -2.306 |
| Net Income
| -626.604 | -559.017 | -523.901 | -438.16 | -251.576 | -128.081 | -79 | -142.11 | -170.447 | -93.753 | -51.574 | -26.235 | 30.905 |
| Net Income Ratio
| -0.668 | -0.8 | -0.973 | -1.151 | -0.82 | -0.484 | -0.406 | -1.718 | -4.636 | -4.083 | -1.646 | -0.912 | 0.312 |
| EPS
| -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.85 | 0.002 |
| EPS Diluted
| -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.11 | 0.001 |
| EBITDA
| -112.812 | -372.578 | -378.067 | -227.815 | -116.788 | -54.128 | -48.912 | -132.058 | -167.13 | -99.413 | -42.871 | -24.104 | 33.453 |
| EBITDA Ratio
| -0.12 | -0.533 | -0.702 | -0.598 | -0.38 | -0.204 | -0.252 | -1.597 | -4.546 | -4.329 | -1.369 | -0.838 | 0.338 |